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Effect of γ-lactones and γ-lactams 
compounds on Streptococcus mutans 
biofilms
Considering oral diseases, antibiofilm compounds can decrease the 
accumulation of pathogenic species such as Streptococcus mutans at 
micro-areas of teeth, dental restorations or implant-supported prostheses. 
Objective: To assess the effect of thirteen different novel lactam-based 
compounds on the inhibition of S. mutans biofilm formation. Material and 
methods: We synthesized compounds based on γ-lactones analogues from 
rubrolides by a mucochloric acid process and converted them into their 
corresponding γ-hydroxy-γ-lactams by a reaction with isobutylamine and 
propylamine. Compounds concentrations ranging from 0.17 up to 87.5 μg 
mL-1 were tested against S. mutans. We diluted the exponential cultures 
in TSB and incubated them (37°C) in the presence of different γ-lactones 
or γ-lactams dilutions. Afterwards, we measured the planktonic growth by 
optical density at 630 nm and therefore assessed the biofilm density by the 
crystal violet staining method. Results: Twelve compounds were active against 
biofilm formation, showing no effect on bacterial viability. Only one compound 
was inactive against both planktonic and biofilm growth. The highest biofilm 
inhibition (inhibition rate above 60%) was obtained for two compounds while 
three other compounds revealed an inhibition rate above 40%. Conclusions: 
Twelve of the thirteen compounds revealed effective inhibition of S. mutans 
biofilm formation, with eight of them showing a specific antibiofilm effect.
Keywords: Lactones. Lactams. Biofilm. Antimicrobial. Streptococcus 
mutans.
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Introduction
Biofilm consists in a complex microbial community 
embedded in an exopolymeric matrix based on 
polysaccharides, glycoproteins, nucleic acids and 
water13,26. Biofilms are found in nature adhered 
to different surfaces depending on nutritional and 
environmental conditions, such as oxygen, pH and 
nutrients. Factors related to the surface itself, like 
chemical composition, surface energy and roughness, 
also affect biofilm formation and development2,13. In 
oral environment, biofilm accumulation by pathogenic 
microorganisms is associated to oral diseases, such as 
gingivitis, periodontitis, peri-implantitis and caries13,22. 
Over the last decades, conventional therapy on the 
use of antimicrobial agents targeting bacterial cell 
viability has significantly decreased the impact of 
infectious diseases. Nevertheless, such achievement 
has stimulated the development of microbial resistance 
to antibiotics1,4,5,20.
The development of new antimicrobial compounds 
targeting bacterial virulence instead of bacterial 
viability is a promising strategy for the prevention 
and treatment of infectious diseases, avoiding the 
stimulation of microbial resistance. In addition, novel 
anti-virulence drugs should disturb the adherence 
of pathogenic species to biotic and abiotic surfaces, 
eliminating the infection by the host immune system. 
Furthermore, virulence-targeted drugs can be 
associated with conventional antibiotics to improve 
their effectiveness1,4,5,20.
Considering oral diseases, antibiofilm compounds 
can decrease the presence of pathogenic species 
such Streptococcus mutans on exposed and retentive 
micro-areas of teeth, dental restorations or implant-
supported prostheses10,21. For adhesion to oral surfaces, 
S. mutans produces extracellular polysaccharides that 
protect the consortia of bacteria against antimicrobial 
substances (e.g. antibiotics)3,13,23. Biofilms involving 
significant S. mutans concentration result in a release 
of high content of lactic acid that decreases the local 
pH, leading to the demineralization of tooth tissues 
and restorative structural materials13,21.
Studies on the formation and inhibition of biofilms 
discovered bacterial-communication systems – 
namely, quorum sensing (QS), which orchestrate 
important temporal events during the infection 
process6,7,24. Natural quorum sensing inhibitors (QSIs), 
such as halogenated furanones derivatives, have 
revealed inhibitory activity on the expression of several 
virulence factors in Pseudomonas aeruginosa biofilms, 
increasing the sensitivity of the biofilm to conventional 
antibiotics8,9. On oral Streptococci, brominated 
furanones were able to inhibit biofilm formation 
without affecting planktonic growth12. That is an 
important feature to avoid in the future development 
of drug resistance. However, previous studies have 
reported a high chemical reactivity and cytotoxicity of 
furanones and some of their derivatives8,9, which led 
to the development of similar synthetic biocompatible 
compounds, such as γ-lactones and their derived 
γ-lactams. Different lactam-based compounds have 
demonstrated potential effect on biofilm inhibition, 
providing an alternative therapeutic approach for 
the treatment of biofilm-related chronic infectious 
diseases11,15,16.
Previous studies revealed that synthetic lactams 
and lactones, similar to natural rubrolides, were 
mainly active against Enterococcus faecalis biofilms16. 
On another study, a group of 28 lactones and lactams 
were tested against different biofilms produced by 
Staphylococcus aureus, Pseudomonas aeruginosa, 
Staphylococcus epidermidis and Streptococcus 
mutans. Several compounds showed biofilm inhibition 
activity against all the species mentioned, particularly 
on S. epidermidis and P. aeruginosa15. Such results 
encourage the development of further experiments 
to identify other lactones and lactams as potential 
antibiofilm agents to be used in the control of infections 
by oral pathogens.
Thus, the aim of this study was to assess the 
effect of thirteen novel synthetic compounds based 
on γ-lactones or γ-lactams on the inhibition of 
Streptococcus mutans biofilms. We hypothesized that 
γ-lactones and γ-lactams could inhibit the S. mutans 
biofilm formation without interfering in microbial 
growth, avoiding the development of bacterial 
resistance.
Material and methods
Bacterial strains and growth conditions
S. mutans ATCC 25175 were microaerophilically 
grown for 48 h at 37°C in agar plates with 32 g/L 
of BHI agar (Bacto, Difco, Radnor, Pennsylvania, 
USA). Bacterial cells were inoculated in Tryptic Soy 
Broth (TSB, Bacto, Difco, Radnor, Pennsylvania, USA) 
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supplemented with 200 g/L sucrose for 24 h at 37°C 
and 150 rpm. After incubation, cells were harvested 
by centrifugation for 10 min at 4°C and 5000 rpm 
and washed twice with Phosphate Buffer Solution 
(PBS, Sigma-Aldrich, St. Louis, Missouri, USA). Then, 
cells were re-suspended in TSB supplemented with 
200 g/L sucrose to obtain an optical density (OD) of 
about 0.6 at Abs630, corresponding to approximately 
1×108 CFU/mL. We measured the OD at 630 nm using 
a spectrophotometer (Tecan Infinite M200, Meilen, 
Zurich, Switzerland)15,16,18,19.
Synthesis of antibiofilm compounds
We synthesized thirteen different anti-biofilm 
compounds based on γ-lactones and γ-lactams for 
biofilm assays. Afterwards, we synthesized compounds 
formulated with rubrolides-based γ-lactones by 
mucochloric acid treatment (Figure 1). Then, we 
converted γ-lactones into their corresponding 
γ-hydroxy-γ-lactams by a reaction with isobutylamine 
and propylamine, as described by Pereira, et al.15 
(2014). A regioselective Suzuki-Miyaura cross-
coupling between lactones and arylboronic acids in 
the presence of Ag2O, AsPh3 and catalytic amount 
of PdCl2(MeCN)2 resulted in the formation of 4-aryl-
3-bromofuran-2(5H)-ones in low yields (26-37%). 
The low conversions of these Suzuki cross-couplings 
reactions can be explained in part by the formation of 
the biphenyls 2,20-dimethoxybiphenyl, 5,50-dibromo-
2,20-dimethoxybiphenyl, 5,50-dimethyl-2,20-
d ime t hoxyb i p heny l ,  a nd  5 , 50 - d i c h l o r o -
2,20-dimethoxybiphenyl produced in 14-23% 
as a result of the homocoupling of the boronic 
acids17. On the next step, we treated 4-aryl-3-
bromofuran-2(5H)-ones with aromatic aldehyde, 
tert-butyldimethylsilyl trifluoromethanesulfonate 
(TBDMSOTf), diisopropylethylamine (DIPEA) followed 
by treatment of the silyl ether generated in situ 
with DBU. A subsequent treatment of the resultant 
compounds with an excess of isobutylamine resulted 
in the formation of the corresponding g-hydroxy-g-
lactams in good yields (76-85%). All spectroscopic and 
physical characterization for the compounds were in 
agreement with the values reported on supplementary 
information described in previous studies15-17.
Microbiological assays
All compounds were solubilized in dimethyl 
sulfoxide (DMSO) at 5 mg/mL-1. For the microbiological 
assays, that stock solution was further diluted to 
concentrations ranging from 0.17 up to 87.5 µg/mL-1. 
The DMSO concentration was standardized at 3.5% 
in all microbiological assays, to avoid side effects on 
bacterial growth. Previous results indicated that 3.5% 
DMSO is innocuous both to bacterial growth and biofilm 
formation15,16,18,19.
Biofilm formation assays were performed in 96-well 
plates, each containing 100 µL of S. mutans inoculum 
at 5×108 CFU/mL in TSB supplemented with 20% 
sucrose (w/v) and 3.5% DMSO (v/v) to ensure that 
the concentration of this solvent remained constant 
as the tested molecules were sequentially diluted for 
the inhibition assays. For each assay, we added 100 µL 
of the tested compound (175 µg/mL-1 in 3.5% DMSO) 
to the first well and serially diluted it at a 1:2 ratio 
by transferring 100 µL of its content to the next well, 
down to the final concentration at 0.17 µg/mL. Control 
groups contained all the mentioned components in the 
absence of the inhibitor compound (positive control) 
or in the absence of bacteria (negative control). 
Microplates were incubated at 37°C in a humidified 
chamber for 24 h. Each assay was performed in 
triplicate15,16,18,19.
To assess effects on bacterial growth prior to 
biofilm analyses, we quantified bacterial growth by 
absorbance readings (630 nm) using a microtiter plate 
reader device (Tecan Infinite M200, Meilen, Zurich, 
Switzerland). For biofilm analyses by the crystal 
Figure 1- General structure for the test rubrolides-based γ-lactones compounds
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violet (CV) staining method, we discarded bacterial 
suspensions from the 96-well plates and washed the 
wells three times with distilled water. In each well, we 
added 120-µl CV solution (0.1% w/v) and allowed it 
to stain the adherent biofilm for 15 min. We removed 
the CV solution and washed the wells three times 
with distilled water. Afterwards, we added 120 µl of 
sodium dodecyl sulfate at 1% (w/v) to solubilize the 
CV and determine the optical density of biofilms by 
spectrophotometry at 595 nm (Tecan Infinite M200, 
Meilen, Zurich, Switzerland)15,16,18,19.
Statistical analysis
We statistically analyzed the data by one-way 
ANOVA using the STATISTICA 6.0® software (StatSoft, 
Palo Alto, California, USA). The level of statistical 
significance was set at 0.05. We performed the T-test 
for independent samples to discover which lactams 
significantly affected the inhibition of the S. mutans 
biofilm.
Results
Results obtained for inhibition of planktonic growth 
and biofilm formation of S. mutans are shown in Figure 
2. For each compound tested, values for inhibition 
of planktonic growth and biofilm were indicated as 
percentages of biofilm produced by the positive 
control, at the concentrations that each compound 
showed the highest biofilm inhibitory effect.
Biofilm analyses showed that twelve of the thirteen 
Figure 2- Antibiofilm activity of compounds 1-13, at their most effective concentrations for S. mutans biofilm inhibition. The percent 
inhibition plot data were calculated by taking the measures of the positive control as 100% of biofilm formation
Figure 3- Statistical results for each compound on inhibition of planktonic growth obtained by ANOVA
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Figure 4- Statistical results for each compound on inhibition of biofilm formation obtained by ANOVA
Figure 5- Analysis of variance of the results
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tested compounds were active for inhibition of S. 
mutans biofilm formation. Compound 4 induced biofilm 
formation (at 87.5 µg/mL-1). That was previously 
reported for other rubrolide analogues15. Regarding 
planktonic growth, only compound 8 (at 0.34 µg/
mL-1) revealed a mild inhibitory effect (19%), while 
several compounds were able to induce planktonic 
growth, as illustrated for compound 11 that caused 
35.8% growth induction (at 43.8 µg/mL-1). For a third 
group, represented by compounds 2-6, the effect on 
the planktonic growth was negligible.
As shown in Figure 2, compounds 1-5, 12, and 13 
caused more than 40% biofilm inhibition, at different 
concentration for each compound. Clearly, the most 
active compound was the simple lactone 2, with a 
biofilm inhibition rate of 65% at 0.17 µg/mL-1. The 
chlorine analogue 1 was less active, causing 54% 
biofilm inhibition at 5.44 µg/mL-1. Statistical analysis 
confirmed the significance of the results (Figures 3-5).
In Figure 6, scanning electron microscopy images 
are shown for Streptococcus mutans free of lactam 
effect, lactam powder particle and S. mutans in the 
presence of lactam.
Figure 6- Scanning electron microscopy images of (A-C) Streptococcus mutans free of lactam effect, (D) lactam powder particle and (E-F) 
S. mutans in the presence of lactam
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Discussion
In this study, we evaluated the effects of thirteen 
different compounds based on γ-lactones and 
γ-lactams against S. mutans biofilm formation, 
since some structurally similar lactones and lactams 
had already been previously classified as potential 
antibiofilm agents against other bacterial species15,16. 
Twelve of the thirteen tested compounds were effective 
in inhibiting the S. mutans biofilm formation. Eight of 
the thirteen compounds inhibited S. mutans biofilm 
formation without interfering with bacterial viability, 
as measured by the planktonic growth. Such results 
confirmed the hypothesis proposed in this study on 
the potential of γ-lactones and γ-lactams for the 
development of a new generation of antibacterial 
drugs, targeting bacterial virulence instead of viability. 
Since several tested compounds did not show inhibition 
of bacterial growth while inhibiting biofilm formation, 
it is predicted that these γ-lactones and γ-lactams 
are specifically active against biofilm and less prone 
to induce the development of bacterial resistance.
In a very similar study15, a group of 28 compounds – 
including brominated furanones and their corresponding 
lactams – were assessed for their antibiofilm activity. 
The lactam-based compounds were active against 
biofilm produced by Gram-positive and Gram-negative 
bacteria. Considering S. mutans, nineteen compounds 
were able to inhibit biofilm formation; however, eleven 
of those revealed an inhibition percentage below 15%. 
In our study, the results revealed that twelve of the 
thirteen compounds tested were able to inhibit from 
65% to 5.6% of biofilm formation (Figure 2). The most 
active lactam compounds found in the previous study 
revealed biofilm inhibition percentages at 89, 34, and 
31.7%, respectively, while this study revealed biofilm 
inhibition percentages at 65, 61, and 54.3%.
Previous studies showed reduced CFU counting 
in the biofilm detached from titanium surfaces 
exposed to lactam-derived compounds (1.5×102 
CFU/mL in the presence of lactam and 4×102 CFU/
mL in its absence)26 (Figure 6). The incorporation 
of organic antibiofilm compounds based on lactams 
was successfully carried out in a previous study by 
functionalizing sPEEK (sulphonated poly-ether-ether-
ketone)14. The sulphonation treatment is useful to 
embed therapeutic compounds such as lactam-
based antibiofilms. A significant inhibition of biofilm 
effect was detected on sPEEK surfaces containing 
lactams and, therefore, no effect was noticed on the 
physiologic planktonic growth of S. mutans. Such 
results indicated that the incorporation of lactams 
into materials used for dental rehabilitations, such 
as titanium or sPEEK, represents an effective clinical 
evolution regarding novel biomaterials with specific 
antibiofilm properties14. Additionally, further studies 
could evaluate the incorporation of antibiofilms in 
other polymers, such as poly(lactic-co-glycolic) acid, 
or PLGA, to cover titanium dental abutments or even 
to produce scaffolds for bone regeneration.
The development of biocompatible lactones and 
lactam-based compounds is an important strategy to 
avoid stimulating bacterial resistance1,2,4,5. Besides, 
previous studies had shown that lactams are less 
cytotoxic than furanones8,9 and more reactive against 
biofilm formation than their corresponding lactones15,16. 
It is important to notice that results presented here do 
not preclude that other metabolic pathways, indirectly 
related to biofilm formation, could also be affected at 
different concentrations than those at which the tested 
compounds display antibiofilm activity. The absence 
of a direct dose-dependence correlation for biofilm 
inhibition revealed by several compounds tested could 
be attributed to synergistic or antagonist activities of 
γ-lactones and γ-lactams at different concentrations 
over other metabolic pathways, which could indirectly 
affect biofilm formation or lead to a biofilm inhibition 
at low concentrations15.
Conclusions
This study assessed the effect of thirteen different 
compounds based on γ-lactones and γ-lactams 
against S. mutans biofilm formation. Eight of the 
tested compounds were active against S. mutans 
biofilms without showing a significant interference with 
bacteria viability, as assessed by planktonic growth 
measurements. The most active compounds described 
in this study revealed an inhibition rate at 65% against 
S. mutans biofilm. Thus, compounds tested have great 
potential to inhibit biofilm formation over different 
restorative materials and are good candidates for 
the development of new specific antibiofilm drugs, 
avoiding the development of bacterial resistance. 
Nevertheless, further studies should be performed to 
evaluate their effects against formation of multispecies 
biofilms.
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